Patents Assigned to Virocell Inc.
  • Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs
    Publication number: 20040131701
    Abstract: The present invention provides a method for the treatment of a viral infection in a patient by administration of a bis-peroxovanadium (bpV) compound, a potent class of phosphotyrosyl phosphatase inhibitors. The method can be utilized for the treatment of patients suffering from infections caused by viruses, such as the human immunodeficiency virus (HIV). The bpV compound may be used in combination with various immunomodulators and/or antiviral agents, in particular, 3TC of which it promotes the phosphorylation into the triphosphate form.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 8, 2004
    Applicant: Virocell Inc.
    Inventors: Jean Gosselin, Pierre Borgeat, Louis Flamand, Michel J. Tremblay
  • Agents with leukotriene B4-like activity as antiherpes viral agents
    Patent number: 6093741
    Abstract: The present invention relates to the use of the antiviral activity of exogenous leukotriene B.sub.4 (LTB.sub.4), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal viruses. The present invention also relates to the use of LTB.sub.4 as an anti-neoplastic agent in the prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases. The human and animal viruses are DNA viruses, such as parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxviridae and hepadnaviridae; RNA viruses, such as picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, and filoviridae in general, and Retroviridae such as HIV-1 and HIV-2.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: July 25, 2000
    Assignee: Virocell Inc.
    Inventors: Jean Gosselin, Pierre Borgeat
  • Interleukin-8 as an antiviral and antitumor agent
    Patent number: 5900235
    Abstract: Interleukin-8 (IL-8) and analogs thereof is useful in the treatment of viral infections, caused by human and animal viruses, and cancers caused by oncoviruses.
    Type: Grant
    Filed: July 5, 1996
    Date of Patent: May 4, 1999
    Assignee: Virocell Inc.
    Inventors: Jean Gosselin, Bassam Damaj, Pierre Borgeat
  • Leukotriene B4 as an antiviral and anti-neoplastic agent
    Patent number: 5789441
    Abstract: The present invention relates to the use of the antiviral activity of leukotriene B.sub.4 (LTB.sub.4), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal viruses. The present invention also relates to the use of LTB.sub.4 as an anti-neoplastic agent in the prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases. The human and animal viruses are DNA viruses, such as parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxviridae and hepadnaviridae; RNA viruses, such as picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, oncornaviridae and filoviridae in general, and Retroviridae such as HIV-1 and HIV-2.
    Type: Grant
    Filed: February 11, 1997
    Date of Patent: August 4, 1998
    Assignee: Virocell Inc.
    Inventors: Jean Gosselin, Pierre Borgeat